Product Overview

• Euvichol-Plus^®
• rCRM₁₉₇
• EcML^®
• COVID-19 Diagnostic Kit

rCRM₁₉₇

rCRM₁₉₇ is a carrier protein produced from genetically modified E. coli (Patent# 10-2099342) and has demonstrated non-inferiority to the natural form made from diphtheria toxoid CRM₁₉₇. Provided that multiple antigens are not chemically linked to the protein, they have lower immunogenicity for pediatric use, therefore, they’re developed as conjugate vaccines. The protein in conjugate vaccines is referred as a carrier protein.
CRM₁₉₇ is commonly used as a carrier protein in protein-polysaccharide conjugation, and CRM₁₉₇ has many advantages over other carrier proteins, i.e. diphtheria toxoid or tetanus toxoid proteins. Our rCRM₁₉₇ can be mass-produced from genetically modified E. coli at higher yield. It is currently used for the development of Typhoid Conjugate Vaccine (TCV), Meningococcal Conjugate Vaccine (MCV), and Pneumococcal Conjugate Vaccine (PCV) under development.

Product Name	Immune-Enhancing Carrier protein, rCRM197
Product Purpose	For research purpose and at GMP grade for vaccine development
Usage	Carrier protein enhancing the immunogenicity